This inventor holds 3 USPTO granted patents. Top assignee: Cangene Corporation. Active years: 1997-2000.
Location History:
- Beeton, CA (1997)
- Cambridge, GB (1999 - 2000)
Company Filing History:
Years Active: 1997-2000
Title: Michael J Butler: Innovator in Protein Expression Technologies
Introduction
Michael J Butler is a distinguished inventor based in Cambridge, GB. He has made significant contributions to the field of protein expression, holding a total of 3 patents. His work focuses on improving the efficiency and effectiveness of protein production in bacterial host cells.
Latest Patents
One of his latest patents is titled "Method for expression of proteins in bacterial host cells." This invention utilizes an aminopeptidase inhibitor to enhance the expression of heterologous proteins in bacterial hosts, such as Streptomyces. The inhibitor prevents the degradation of these proteins by aminopeptidases, which is crucial for maintaining protein integrity during production. Another notable patent is "Streptomyces proteases and methods for improved secretion of." This patent identifies a family of proteases that degrade heterologous proteins secreted from Streptomyces cells. The invention includes the design of irreversible inhibitors based on the mechanisms and substrate specificity of the target proteases, as well as methods for selecting hosts that secrete high amounts of proteases.
Career Highlights
Michael J Butler is currently associated with Cangene Corporation, where he continues to advance his research in protein expression technologies. His innovative approaches have positioned him as a key figure in the biotechnology sector.
Collaborations
He has collaborated with notable colleagues, including Timothy J Krieger and Gisela Soostmeyer, contributing to a dynamic research environment that fosters innovation.
Conclusion
Michael J Butler's work in protein expression technologies has led to significant advancements in the field, underscoring his role as a leading inventor. His contributions continue to impact the biotechnology industry positively.